The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia

Fazal-i-Akbar Danish,1 Saeeda Yasmin21James Paget University Hospital, Great Yarmouth, Norfolk, United Kingdom; 2Shifa International Hospital, Islamabad, PakistanAbstract: Eltrombopag is a 2nd generation thrombopoietin-receptor agonist. It binds with the thrombopoietin-receptors found on the surface...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Danish FA, Yasmin S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/29cea24ddb364303ac2f984376a6d7ab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:29cea24ddb364303ac2f984376a6d7ab
record_format	dspace
spelling	oai:doaj.org-article:29cea24ddb364303ac2f984376a6d7ab2021-12-02T03:17:20ZThe role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia1179-1535https://doaj.org/article/29cea24ddb364303ac2f984376a6d7ab2013-03-01T00:00:00Zhttp://www.dovepress.com/the-role-of-eltrombopag-in-the-management-of-hepatitis-c-virus-related-a12474https://doaj.org/toc/1179-1535Fazal-i-Akbar Danish,1 Saeeda Yasmin21James Paget University Hospital, Great Yarmouth, Norfolk, United Kingdom; 2Shifa International Hospital, Islamabad, PakistanAbstract: Eltrombopag is a 2nd generation thrombopoietin-receptor agonist. It binds with the thrombopoietin-receptors found on the surfaces of the megakaryocytes &amp; increases platelet production. Many recent studies have suggested a potential role for this novel agent in the treatment of thrombocytopenia associated with hepatitis-C infection. Studies have shown that adjunct treatment with Eltrombopag can help avoid dose reductions/withdrawals of pegylated interferon secondary to thrombocytopenia. It may also have a role in priming up platelet levels to help initiate antiviral therapy. Similarly, chronic liver disease patients with thrombocytopenia who need to undergo an invasive procedure may be potential candidates for short two-week courses of eltrombopag in the periprocedural period to help reduce the risk of bleeding. Besides the price (deemed very expensive and probably not cost-effective), there are some legitimate concerns about the safety profile of this novel agent (most importantly, portal vein thrombosis, bone marrow fibrosis and hepatotoxicity). In this article, the potential role of eltrombopag in the context of hepatitis C virus (HCV)-related thrombocytopenia is reviewed. To write this article, a MEDLINE search was conducted (1990 to November 2012) using the search terms &ldquo;eltrombopag,&rdquo; &ldquo;HCV,&rdquo; and &ldquo;thrombocytopenia.&rdquo;Keywords: liver disease, chronic immune thrombocytopenic purpura, thrombopoietin-receptor agonist, romiplostimDanish FAYasmin SDove Medical PressarticleDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol 2013, Iss default, Pp 17-30 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Diseases of the digestive system. Gastroenterology RC799-869 Danish FA Yasmin S The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
description	Fazal-i-Akbar Danish,1 Saeeda Yasmin21James Paget University Hospital, Great Yarmouth, Norfolk, United Kingdom; 2Shifa International Hospital, Islamabad, PakistanAbstract: Eltrombopag is a 2nd generation thrombopoietin-receptor agonist. It binds with the thrombopoietin-receptors found on the surfaces of the megakaryocytes &amp; increases platelet production. Many recent studies have suggested a potential role for this novel agent in the treatment of thrombocytopenia associated with hepatitis-C infection. Studies have shown that adjunct treatment with Eltrombopag can help avoid dose reductions/withdrawals of pegylated interferon secondary to thrombocytopenia. It may also have a role in priming up platelet levels to help initiate antiviral therapy. Similarly, chronic liver disease patients with thrombocytopenia who need to undergo an invasive procedure may be potential candidates for short two-week courses of eltrombopag in the periprocedural period to help reduce the risk of bleeding. Besides the price (deemed very expensive and probably not cost-effective), there are some legitimate concerns about the safety profile of this novel agent (most importantly, portal vein thrombosis, bone marrow fibrosis and hepatotoxicity). In this article, the potential role of eltrombopag in the context of hepatitis C virus (HCV)-related thrombocytopenia is reviewed. To write this article, a MEDLINE search was conducted (1990 to November 2012) using the search terms &ldquo;eltrombopag,&rdquo; &ldquo;HCV,&rdquo; and &ldquo;thrombocytopenia.&rdquo;Keywords: liver disease, chronic immune thrombocytopenic purpura, thrombopoietin-receptor agonist, romiplostim
format	article
author	Danish FA Yasmin S
author_facet	Danish FA Yasmin S
author_sort	Danish FA
title	The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
title_short	The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
title_full	The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
title_fullStr	The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
title_full_unstemmed	The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
title_sort	role of eltrombopag in the management of hepatitis c virus-related thrombocytopenia
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/29cea24ddb364303ac2f984376a6d7ab
work_keys_str_mv	AT danishfa theroleofeltrombopaginthemanagementofhepatitiscvirusrelatedthrombocytopenia AT yasmins theroleofeltrombopaginthemanagementofhepatitiscvirusrelatedthrombocytopenia AT danishfa roleofeltrombopaginthemanagementofhepatitiscvirusrelatedthrombocytopenia AT yasmins roleofeltrombopaginthemanagementofhepatitiscvirusrelatedthrombocytopenia
_version_	1718401842604408832

The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia

Ejemplares similares